Agile Therapeutics, Inc. (AGRX) Reaches $0.59 1 Year Low; Nuveen Senior Income Fund Has 1.1 Sentiment

May 27, 2018 - By Dolores Ford

Agile Therapeutics, Inc. (NASDAQ:AGRX) Logo

Nuveen Senior Income Fund (NSL) investors sentiment increased to 1.1 in Q4 2017. It’s up 0.04, from 1.06 in 2017Q3. The ratio increased, as 23 hedge funds increased or started new holdings, while 21 reduced and sold holdings in Nuveen Senior Income Fund. The hedge funds in our database now hold: 8.51 million shares, up from 7.74 million shares in 2017Q3. Also, the number of hedge funds holding Nuveen Senior Income Fund in top ten holdings was flat from 0 to 0 for the same number . Sold All: 9 Reduced: 12 Increased: 12 New Position: 11.

The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) hit a new 52-week low and has $0.54 target or 9.00% below today’s $0.59 share price. The 8 months bearish chart indicates high risk for the $20.21M company. The 1-year low was reported on May, 27 by If the $0.54 price target is reached, the company will be worth $1.82 million less. The stock decreased 4.07% or $0.03 during the last trading session, reaching $0.59. About 602,460 shares traded or 50.72% up from the average. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 11.00% since May 27, 2017 and is downtrending. It has underperformed by 22.55% the S&P500.

Livingston Group Asset Management Co (Operating As Southport Capital Management) holds 0.5% of its portfolio in Nuveen Senior Income Fund for 202,308 shares. Shaker Financial Services Llc owns 74,281 shares or 0.23% of their US portfolio. Moreover, Brick & Kyle Associates has 0.15% invested in the company for 28,399 shares. The New York-based Mariner Investment Group Llc has invested 0.14% in the stock. E&G Advisors Lp, a Texas-based fund reported 46,000 shares.

The stock decreased 0.15% or $0.01 during the last trading session, reaching $6.49. About 49,094 shares traded. Nuveen Senior Income Fund (NSL) has declined 5.39% since May 27, 2017 and is downtrending. It has underperformed by 16.94% the S&P500.

Investors sentiment increased to 1.71 in Q4 2017. Its up 0.36, from 1.35 in 2017Q3. It increased, as 11 investors sold Agile Therapeutics, Inc. shares while 6 reduced holdings. 13 funds opened positions while 16 raised stakes. 22.48 million shares or 2.92% less from 23.16 million shares in 2017Q3 were reported. Moreover, Meeder Asset Mngmt Inc has 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX). Investor has 3.51 million shares. Northern Trust Corp invested in 38,075 shares. Proquest Assocs Iv Limited Liability Corporation accumulated 5.06M shares. Royal Bancshares Of Canada holds 0% or 311,328 shares in its portfolio. Jacobs Levy Equity reported 0% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). Franklin Resource has 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 2.87 million shares. Savings Bank Of Montreal Can owns 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 1,350 shares. Wells Fargo And Mn stated it has 0% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). Commercial Bank Of New York Mellon Corporation holds 38,920 shares. Alpine Global Llc owns 0.01% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 22,001 shares. Goldman Sachs Gp owns 15,105 shares. Art Advisors Limited Liability Corporation holds 0% or 36,431 shares in its portfolio. Panagora Asset holds 0% or 16,649 shares in its portfolio. Geode Cap Management Ltd Liability Co invested in 0% or 171,318 shares.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $20.21 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

More news for Agile Therapeutics, Inc. (NASDAQ:AGRX) were recently published by:, which released: “Agile Therapeutics Reports First Quarter 2018 Financial Results” on May 07, 2018.‘s article titled: “Pre-Open Movers 05/18: (QTNT) (AFSI) (CERN) Higher; (AGRX) (ARQL) (CPB) Lower (more…)” and published on May 18, 2018 is yet another important article.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on July, 27. They expect $-0.17 EPS, up 34.62% or $0.09 from last year’s $-0.26 per share. After $-0.21 actual EPS reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -19.05% EPS growth.

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics had 25 analyst reports since December 30, 2015 according to SRatingsIntel. The stock has “Buy” rating by Noble Financial on Friday, December 22. H.C. Wainwright maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Tuesday, March 13 with “Buy” rating. RBC Capital Markets maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) rating on Friday, July 14. RBC Capital Markets has “Buy” rating and $800 target. The firm has “Buy” rating given on Thursday, November 9 by Noble Financial. The company was maintained on Monday, June 12 by Noble Financial. H.C. Wainwright maintained it with “Buy” rating and $10.0 target in Thursday, October 12 report. On Friday, December 22 the stock rating was downgraded by William Blair to “Hold”. The firm earned “Buy” rating on Wednesday, December 30 by Noble Financial. H.C. Wainwright reinitiated the shares of AGRX in report on Monday, October 2 with “Buy” rating. The rating was maintained by Noble Financial with “Buy” on Friday, July 28.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News